Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis

G Vescovo, F Serafini, L Facchin, P Tenderini, U Carraro, L Dalla Libera, C Catani, G B Ambrosio

Abstract

Objective—In congestive heart failure (CHF) the skeletal muscle of the lower limbs develops a myopathy with atrophy and shift from the slow type to the fast type fibres. The aim was to test the hypothesis that this myopathy is specific and not simply related to detraining, by comparing patients with different degrees of CHF with patients with severe muscle atrophy due to disuse.

Design—Case-control study involving 50-150 μg needle biopsies of the gastrocnemius muscle. By an electrophoretic micromethod, the three isoforms of myosin heavy chains (MHC) were separated.

Patients—Five patients restricted to bed for more than one year because of stroke with disuse atrophy and normal ventricular function, and 19 with CHF were studied. There were seven age matched controls.

Main outcome measures—The percentage of MHC1 (slow isoform), MHC2a (fast oxidative), and MHC2b (fast glycolytic) was determined by densitometric scan and correlated with indices of severity of cardiac failure.

Results—Ejection fraction was 42.5 (SD 15.2)% in CHF, 59.5 (1-0)% in disuse atrophy and 60.3 (1.4)% in controls (P < 0.001 v both). The degree of muscle atrophy as calculated by the body mass index/gastrocnemius cross sectional area, showed a profound degree of atrophy in patients with muscle disuse [0.94 (0.39)]. This was worse than in the controls [4.27 (0.16), P < 0.0005] and the CHF patients [2.60 (1.10), P < 0.005]. Atrophy in CHF patients was also greater than in controls (P < 0.005). MHC1 was lower in CHF than in disuse atrophy [51.83 (15.04) v 84.5 (17.04), P < 0.01] while MHC2b was higher [23.5 (7.4) v 7.25 (7.92), P < 0.001]. There was a similar trend for MHC2a [24.83 (15.01) v 8.25 (9.12), P < 0.05]. Within the CHF group there was a positive correlation between NYHA class and MHC2a (r = 0.47, P < 0.05) and MHC2b (r = 0.55, P < 0.01) and a negative correlation between NYHA class and MHC1 (r = −0.74, P < 0.001). Similarly, significant correlations were found for ejection fraction, diuretic consumption score, exercise test tolerance, and degree of muscle atrophy.

Conclusions—The CHF myopathy appears to be specific and not related to detraining. The magnitude of MHC redistribution correlates with the severity of the disease. The electrophoretic micromethod used is very sensitive and reproducible. Biopsies are so well tolerated that can be repeated frequently, allowing thorough follow up.

(Heart 1996;76:337–343)

Keywords: congestive heart failure; skeletal muscle myopathy; myosin heavy chains; microbiopsies

In congestive heart failure (CHF) lower limb skeletal muscle performance is disordered and this can at least in part explain symptoms such as fatigue and shortness of breath. Lipkin et al initially suggested that quadriceps femoris muscle strength is reduced because of loss of skeletal muscle bulk, although the mean force per unit area was within the normal range. Lipkin et al showed in quadriceps muscle biopsies a shift towards type II fibres with presence of atrophic fibres. Mancini et al reported a shift toward type IIb fibres and atrophy of type IIs in the gastrocnemius muscle. A reduction of type I and a relative increase of IIb was found by Sullivan et al and Drexler et al in needle biopsies from vastus lateralis. Mitochondrial abnormalities also contribute to the myopathy of CHF. Whether these changes in skeletal muscle composition are due to deconditioning induced atrophy, as suggested by several investigators, or represent a specific myopathy is not clear yet. We tested the hypothesis that CHF myopathy is characterised by intrinsic abnormalities by comparing the skeletal muscle myosin heavy chain (MHC) composition in patients with CHF with that of control subjects and of patients with severe disuse atrophy. The study was carried out on fine needle biopsies taken from the gastrocnemius. The three skeletal muscle MHC isoforms, namely the slow MHC1 isomyosin, the MHC2a (fast oxidative), and the MHC2b (fast glycolytic), were separated using a high resolution electrophoretic micromethod devised in our laboratories.
Methods

PATIENTS
Nineteen patients with CHF (10 males, nine females) (nine with dilated cardiomyopathy, four with hypertensive heart disease, and six with ischaemic heart disease) were studied. These were all patients whose diagnosis was established by means of clinical history, ECG, exercise test, echocardiography, and coronary angiogram. We also studied five patients (three males, two females) with disuse atrophy who had been restricted in bed for more than one year because of stroke and in whom a rehabilitation programme was unsuccessful. These all were normotensive (BP < 140/95 mm Hg) and had normal cardiac function (ejection fraction ≥ 60%), and had no cross sectional echocardiographic and echo-Doppler cardiac abnormalities. Seven healthy volunteers (four males, three females) with normal medical history, physical examination, normal blood pressure values, ECG, echocardiography, and exercise test tolerance were used as controls. In all the patients the presence of major blood flow abnormalities in the lower limbs was excluded by a Winsor (ankle/brachial) index of ≥ 1.

SKELETAL MUSCLE BIOPSY
Skeletal muscle biopsies were taken from the gastrocnemius muscle using a 17G Histo-Cut soft tissue disposable Menghini needle (Sterylab, Milan, Italy). From each specimen, between 50 and 150 µg of tissue were obtained. The specimen was immediately frozen in liquid nitrogen and kept in a −80°C fridge until processed. In patients with disuse atrophy biopsies were taken from the non-paretic leg in order to avoid muscle hypertonicity. No anaesthesia was employed.

Informed consent was obtained in all the patients.

CARDIOTHORACIC RATIO
Cardiothoracic ratio was calculated in each patient from routine chest x ray.

EXERCISE TOLERANCE TEST
All the patients with CHF and the normal subjects underwent a treadmill exercise test according to a modified Naughton protocol. The protocol envisaged seven stages of three min each at a fixed speed of 3 km/h starting from 0% grade (stage 0) with increments of 3-5%. All subjects exercised to a symptom limited maximum or until they reached theoretical submaximal heart rate.

ECHOCARDIOGRAPHIC MEASUREMENTS
All the CHF, disuse atrophy patients, and control subjects had cross sectional echocardiography and colour Doppler. Ejection fraction, left ventricle end diastolic diameter (LVEDD), left ventricle end systolic diameter (LVESD); and A wave/E wave ratio were calculated with an apical four chamber approach. Ejection fraction was calculated with the modified Simpson method.

NYHA CLASS
New York Heart Association (NYHA) class was assessed in all the patients.

DIURETIC CONSUMPTION
Patients were divided into five classes according to diuretic consumption. Class 1 was no diuretic, class 2, 20 to 40 mg of frusemide or a thiazide diuretic a day, class 3 ≥ 40 mg frusemide, class 4 ≥ 80 mg, class 5 ≥ 120 mg.

INDEX OF MUSCLE ATROPHY
We used the gastrocnemius cross sectional area to body mass index (BMI) ratio to assess the degree of muscle atrophy. Cross sectional area was measured with a computerised tomography scan. Transverse images were obtained in the same location on each leg one third distal to the popliteal space.

ELECTROPHORETIC SEPARATION OF MHC
The method is an improvement of that developed by Carraro et al. Biopsies were solubilised in 100–200 µL of 2–3% sodium dodecyl sulphate (SDS), 10% glycerol, 0-5% 2-mercaptoethanol, and 62.5 mM Tris-HCl pH 6-8 and boiled for five min. The running buffer was added to the sample in a ratio of 1:1 vol/vol. Analytical SDS page of MHC was performed on 7% polyacrylamide slabs, prepared according to Laemmli, but 37.5% vol/vol glycerol was present in both the separating and the stacking gel. The stacking gel was composed of 37.5% glycerol, 4% Tris-acrylamide-Bis (36:5:1), 12-5 mM Tris-HCl (pH 6-8), and 0-1% SDS. The separating gel was composed of 37-5% glycerol, 7% Tris-acrylamide-Bis (36:5:1), 375 mM Tris-HCl (pH 8-8), and 0-1% SDS. Running buffer was made of 50 mM Tris, 384 mM glycine, pH 8-3, and 0-2% SDS. Separation of MHC was achieved using constant current at 4 mA (corresponding to about 40 V). After 6–8 h the running buffer was changed and electrophoresis restarted with the same parameters. After 24 h the voltage rises to about 130–160 V and the run is stopped. Gels containing approximately 0-2 µg of protein per band are usually stained with 0-1% Coomassie brilliant blue in 5% acetic acid/40% methanol and destained with 40% methanol/7% acetic acid. Some gels with less than 0-1 µg protein loaded were afterward stained with the silver method. Identification of individual MHCs was performed by immunoblotting the gel bands with a panel of monoclonal antibodies (generous gift of Prof S Schiaffino).12,14

ASSESSMENT OF MHC CONTENT
The percent distribution of MHC1, MHC2a, and MHC2b was determined by densitometric scan of the stained slab gels. A GS300 transmittance reflectance scanning densitometer (Hoefer Scientific Instruments) connected to a McIntosh SE Apple computer was used. Data were processed with a GS370 densitometry software. A linear response is attained on densitometry when 0-1–2 µg of individual MHC is analysed. Quantitative densitometry was performed using internal MHC standards electrophoresed in the same gel.16
Evidence for a specific skeletal myopathy in heart failure

STATISTICAL ANALYSIS

Coefﬁcient of variation, Student t test for unpaired data, mean (SD), and linear regression are used where appropriate.

Results

Age did not dier signiﬁcantly in the three groups of patients, being 71.2 (7.6) years in the CHF group, 71.0 (8.1) in the disuse atrophy patients, and 55.4 (8.5) in the control subjects.

NYHA CLASS

Of the CHF patients, four were in NYHA class I, four in class II, eight in class III, and three in class IV.

ECHOCARDIOGRAPHIC INDICES

Ejection fraction was 42.5 (15.2)% (n = 17) in CHF patients. This was signiﬁcantly lower (P < 0.001) than in either disuse atrophy or control subjects [59.5 (1.0), n = 5, and 60.3 (1.4), n = 7, respectively]. There were no signiﬁcant differences between the two latter groups, neither were there signiﬁcant differences in LVESD between CHF, disuse atrophy, and control subjects [39.7 (13.5) mm, 29.0 (2.9) mm, and 32.0 (1.1) mm, respectively], although there was a trend in CHF patients for slightly higher values (P = 0.1). LVEDD values showed a similar trend, being 57.8 (11.8) mm in CHF, 54.1 (11.2) mm in disuse atrophy, and 55.1 (12.8) mm in controls.

NYHA class, age, sex, and myosin heavy chain (MHC) composition in congestive heart failure (CHF), disuse atrophy, and control patients

<table>
<thead>
<tr>
<th>CHF</th>
<th>MHC%</th>
<th>Disuse atrophy</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYHA</td>
<td>Age/sex</td>
<td>1</td>
<td>2a</td>
</tr>
<tr>
<td>Disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DCM II</td>
<td>54/M</td>
<td>52</td>
<td>30</td>
</tr>
<tr>
<td>DCM II</td>
<td>73/F</td>
<td>64</td>
<td>23</td>
</tr>
<tr>
<td>DCM III</td>
<td>73/M</td>
<td>71</td>
<td>8</td>
</tr>
<tr>
<td>HYP III</td>
<td>71/F</td>
<td>44</td>
<td>21</td>
</tr>
<tr>
<td>HYP IV</td>
<td>69/M</td>
<td>48</td>
<td>23</td>
</tr>
<tr>
<td>HYP I</td>
<td>71/M</td>
<td>81</td>
<td>10</td>
</tr>
<tr>
<td>HYP IV</td>
<td>84/M</td>
<td>28</td>
<td>42</td>
</tr>
<tr>
<td>HYP IV</td>
<td>69/F</td>
<td>50</td>
<td>21</td>
</tr>
<tr>
<td>HYP IV</td>
<td>65/M</td>
<td>64</td>
<td>0</td>
</tr>
<tr>
<td>HYP IV</td>
<td>75/M</td>
<td>46</td>
<td>22</td>
</tr>
<tr>
<td>HYP IV</td>
<td>81/F</td>
<td>43</td>
<td>51</td>
</tr>
<tr>
<td>HYP IV</td>
<td>81/F</td>
<td>19</td>
<td>58</td>
</tr>
<tr>
<td>HYP IV</td>
<td>71/M</td>
<td>69</td>
<td>16</td>
</tr>
<tr>
<td>HYP IV</td>
<td>74/F</td>
<td>43</td>
<td>38</td>
</tr>
<tr>
<td>HYP IV</td>
<td>74/M</td>
<td>47</td>
<td>33</td>
</tr>
<tr>
<td>HYP IV</td>
<td>69/M</td>
<td>64</td>
<td>11</td>
</tr>
<tr>
<td>HYP IV</td>
<td>69/F</td>
<td>54</td>
<td>16</td>
</tr>
<tr>
<td>HYP IV</td>
<td>56/F</td>
<td>64</td>
<td>23</td>
</tr>
<tr>
<td>HYP IV</td>
<td>73/M</td>
<td>72</td>
<td>11</td>
</tr>
</tbody>
</table>

DCM, dilated cardiomyopathy; HYP, hypertensive heart disease; IHD, ischaemic heart disease; NYHA, New York Heart Association functional class.
Figure 3 Myosin heavy chain 2a (MHC2a) composition in congestive heart failure (CHF), control subjects, and disuse atrophy patients. aa P < 0.05; bb P = NS; cc P < 0.05.

MYOSIN HEAVY CHAIN COMPOSITION
MHC isoforms were separated by SDS-page as described in Methods and presented in fig 1. In human skeletal muscle three MHC isoforms are usually separated on the basis of their relative mobility, in the order of fastest to slowest, MHC1, MHC2a, MHC2b. Sometimes the 2a band splits allowing the identification of the fast MHC2x component. When such a separation occurs we included the 2x band in the 2a for quantitation. Although the physiological meaning of the 2x is still debated, its function seems similar to that of 2a and it is therefore assimilable. 14 MHC composition in CHF, disuse atrophy, and control subjects is summarised in the table. CHF patients showed a significantly lower percentage of MHC1 than control subjects [51-83 (15-04) vs 68-0 (10-2) P < 0.01] and a slightly higher, though not significant, percentage of MHC2a [24-83 (15-01) vs 20-86 (8-35), P = NS] and MHC2b [23-5 (7-45) vs 11-14 (8-71), P < 0.01]. Surprisingly, disuse atrophy patients showed a remarkable shift toward the slow isoforms. In fact the percentage of MHC1 was significantly higher [84-50 (17-04)] than that of CHF patients (P < 0.01) and showed a trend toward significance when compared to that of control patients (P < 0.1) (fig 2). On the other hand there was a decrease in both the percentage of MHC2a [8-25 (9-12)] and MHC2b [7-25 (7-92)]. The percentage of the fast oxidative fibres was significantly smaller than in the CHF patients and controls (P < 0.05 for both) (fig 3). The fast glycolytic myosin percentage was significantly lower than in the CHF patients (P < 0.001) (fig 4).

CORRELATION BETWEEN MHC COMPOSITION AND CLINICAL SEVERITY OF CHF
Clinical indices of the severity of heart failure were correlated with MHC composition in patients with CHF and controls.

NYHA class
There was a negative correlation between percentage of MHC1 and NYHA class (r = 0.74, P < 0.001), and a positive correlation between NYHA class and MHC2a (r = 0.47, P < 0.05) and MHC2b (r = 0.55, P < 0.01) (fig 5).

Ejection fraction
Ejection fraction correlated positively with MHC1 (r = 0.65, P < 0.001) and negatively with MHC2a (r = −0.75, P < 0.001). Although there was a trend for MHC2b to decrease in patients with higher ejection fraction, this did not reach statistical significance (r = 0.26, P = NS) (fig 6).

Figure 4 Myosin heavy chain 2b (MHC2b) composition in congestive heart failure (CHF), control subjects, and disuse atrophy patients. aa P < 0.01; bb P < 0.001; cc P = NS.

Figure 5 Correlation between the three myosin heavy chain (MHC) isoforms and New York Heart Association (NYHA) class.

Figure 6 Correlation between the three myosin heavy chain (MHC) isoforms and ejection fraction.
Evidence for a specific skeletal myopathy in heart failure

There was no significant correlation between MHC composition and either LVEDD or LVESD, although there was a trend for LVESD to correlate negatively with MHC1.

Degree of muscle atrophy

Combining the data from CHF and control subjects, there was a significant positive correlation between the BMI/CSA ratio index and MHC1 \( (r = 0.44, P < 0.05) \). MHC2b was negatively correlated with BMI/CSA \( (r = -0.49, P < 0.05) \). There was no correlation with MHC2a \( (r = 0.10, P = NS) \) (fig 9).

Reproducibility of the method

Five biopsies were taken from the same subject with CHF and processed separately. Samples from the five different biopsies were loaded on the same slab gel. The coefficient of variation between the five samples was 5% for MHC1, 5% for MHC2a, and 7% for MHC2b. We also loaded on five separate SDS-page samples from one patient. Electrophoreses were carried out on separate days, and the sample—once solubilised in SDS, 2-mercaptoethanol, and Tris-HCI—was kept in a fridge at \(-10^\circ C\) until the next experiment was done. The coefficient of variation was 4% for MHC1, 6% for MHC2a, and 4% for MHC2b.

Discussion

Our study shows a decrease in the percentage of type I skeletal muscle MHC and an increase in the percentage of type II in patients with CHF of different aetiologies. The percentage of MHC1 in CHF subjects was 25% less than that of controls, while the fast glycolytic isoform 2b nearly doubled, being 52% higher. The shift toward fibres which possess a lower oxidative capacity is consistent with published reports of phosphocreatine depletion,\(^{17}\) acidosis,\(^{18}\) and enzymatic alterations.\(^{19, 20}\)

Our data are in agreement with those of Lipkin et al\(^ {14}\) who described a decrease in type I fibres and those of Mancini et al\(^ {14}\) and Sullivan et al\(^ {20}\) who reported an increased percentage of fast twitch IIb fibres and atrophy of type I slow twitch fibres. Similar results have been reported by Sabbah et al\(^ {15}\) in dogs with congestive heart failure. These changes have been ascribed to intrinsic skeletal muscle abnormalities\(^ {21}\) and only in part to muscle underperfusion. Moreover Wilson et al suggested that exertional fatigue is due to skeletal muscle abnormalities and not to reduced blood flow.\(^ {22}\) Atrophy due to muscle deconditioning\(^ {18}\) has been claimed to be primarily responsible for these muscle alterations.

Our data do not entirely support the hypothesis that prolonged immobilisation is the cause of changes in MHC composition of skeletal muscle. In fact our patients with diastolic atrophy, though there were only five, showed a shift toward the slow MHC1 myosin and thus their behaviour was opposite to CHF patients. On the other hand the degree of muscle atrophy within the control and CHF patients correlated with the progressive decrease in MHC1 and

**Figure 7** Correlation between the three myosin heavy chain (MHC) isoforms and diuretic consumption.

**Figure 8** Correlation between the three myosin heavy chain (MHC) isoforms and exercise tolerance.

**Figure 9** Correlation between the three myosin heavy chain (MHC) isoforms and degree of muscle atrophy (gastrocnemius cross sectional area/body mass index (CSA/BMI)).

**Diuretic consumption**

Diuretic consumption score correlated negatively with MHC1 \( (r = -0.62, P < 0.001) \) and positively with MHC2a \( (r = 0.35, P < 0.1) \) and MHC 2b \( (r = 0.49, P < 0.001) \) (fig 7).

**Exercise test tolerance**

There were significant correlations between steps reached on the treadmill and MHC composition. The correlation was positive for MHC1 \( (r = 0.65, P < 0.001) \) and negative for MHC2a \( (r = -0.37, P < 0.05) \) and MHC 2b \( (r = -0.57, P < 0.01) \) (fig 8).
increase of MHC2b content. We also found a correlation between MHC composition and indicators of severity of CHF such as NYHA class, exercise tolerance, diuretic consumption, and ejection fraction. It seems that patients with CHF have a specific myopathy, the severity of which is related to that of the heart failure syndrome. It may well be that in these patients the correlation between degree of atrophy and MHC composition is simply the reflection of two phenomena heading in the same direction: (1) progressive muscle deconditioning, which in turn leads to muscle wasting and atrophy without changes in fibre distribution, and (2) intrinsic changes in skeletal muscle leading to a shift in the contractile protein pattern. This second phenomenon could resemble what occurs in the heart, where adaptive changes in the isozymic composition of the myocardium are observed during the development of both hypertrophy and failure.

The existence of a specific skeletal muscle myopathy with selective type I fibres atrophy has been reported already by Caforio et al. in patients with cardiomyopathies. Changes in skeletal muscle in CHF are very much the same as those observed in the diaphragm in the rat, where an increased expression of adult fast myosins occurs. Since the synthesis of adult slow myosins is dependent on the activity of motor innervation, while adult fast myosin is expressed in denervated fibres even though the neuronal influences are removed, we cannot exclude a neural contribution to the origin of the myopathy. Coats et al have recently proposed the "ergo- and metabolo-receptors" theory to explain symptoms and muscle wasting in CHF. Chemically sensitive receptors detect muscle work and metabolism and transmit to the central nervous system stimuli that can drive blood pressure responses and increase sympathetic activity. An increased ergoreceptor activity in patients with CHF might maintain the increased sympathetic outflow, with consequent increased peripheral resistances, decreased perfusion, and further muscle deterioration. Alternatively circulating factors such as increased concentrations of tumour necrosis factor or metabolic and vascular alterations like insulin resistance or increased thickness of the endothelial cells can be invoked as determinants of muscle changes.

The novelty of our study is the application to very small biopsies, and for the first time in cardiology, of a high resolution micromethod that allows separation of the three MHCs isoforms from extremely small tissue samples. The reproducibility of this method is fairly high. Fine needle biopsies are extremely easy to perform and so well tolerated that they do not require any sort of anaesthesia. We had no complications in our series of patients. The technique allows serial biopsy sampling in the same patients, making possible the study of either muscle worsening during the progression of the disease or possible improvements due to different therapies such as training or hormonal treatment that may be able to restore muscle bulk, relieve symptoms, and increase exercise tolerance. Study of MHC composition may also have the potential to detect early changes in skeletal muscle composition and correlate them with humoral, biochemical, and functional variables.


